Gentronix and BioQuanta to Distribute Mitoxis-Functional Metabolic Platform.

Gentronix Ltd. (Manchester, United Kingdom), the specialist genotoxicity assay provider and BioQuanta SA (Paris, France), a French company engaged in the implementation of predictive and personalized medicine, have signed an agreement covering the commercialization of the Mitoxis functional metabolomics platform from BioQuant. Mitoxis is a novel assay platform for evaluating the metabolic impact of any molecule, as well as detecting mitochondrial toxicity.

Gentronix will become a worldwide distributor of Mitoxis services giving customers access to over 70 discrete assays central to a deeper understanding of cell health. This comprehensive range of assays covers key functional metabolisms important for the early detection of toxicity liabilities, including the electron-transport chain, oxidative stress, cellular energy status, inflammation, and cell death.

Mitoxis was developed on highly automated analyzers used in clinical biology, and delivers results with the precision of clinical diagnostics. The Mitoxis approach allows the simultaneous analysis of more than 30 parameters on the same reduced sample volume of < 5µL, with limited or no sample preparation. With an overall coefficient of variation (CV) < 4%, intersample variability is lowered, leading to increased confidence in the results and a better understanding of interdependencies between parameters. Mitoxis provides unmatched results to evaluate side effects of exogenous molecules (therapeutic, cosmetic, or industrial) on the main transversal metabolic pathways of the cell.

The platform was developed to meet the same performance criteria of standard operating procedures in place for clinical biology, and it is the result of expertise gained from performing millions of tests per year routinely in a French public hospital.

Dr. Steve Beasley, Commercial Director at Gentronix said, "This agreement allows Gentronix to further expand its range of services across all of the sectors we currently serve to provide our customers access to a wide range of cell health assays of unparalleled accuracy. We have an expanding customer base that will benefit from access to these highly accurate metabolomics assays."

BioQuanta is a biotechnology company engaged in the implementation of predictive and personalized medicine. The company aims to become a major player in the biopharmaceutical R&D by contributing to the development of innovative drugs, and powerful diagnostic solutions to categorize patients.

Gentronix provides services and solutions that ensure safer products across a wide range of chemistry driven industries. The company's primary focus is on providing better hazard identification assays for genotoxicity through the use of its patented human cell GADD45a reporter assays GreenScreen HC and BlueScreen HC. Gentronix provides contract services for genotoxicity in these and related assays including Ames, Comet and Micronucleus tests, as well as a wide range of ADME and predictive toxicity endpoints.

Related Links:
Gentronix Ltd.
BioQuanta SA